McMillan Shakespeare Ltd (ASX: MMS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
McMillan Shakespeare Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
McMillan Shakespeare Ltd (ASX: MMS)
Latest News
Earnings Results
These 9 ASX shares revealed some of the biggest profit rises this earnings season
Earnings Results
ASX All Ords stock volatile despite 158% profit surge in FY24
Broker Notes
3 fantastic ASX stocks to buy in August
Dividend Investing
Which ASX dividend shares are predicted to have the highest yields in FY25?
Earnings Results
3 ASX All Ords stocks surging 10% to 46% on earnings results
Financial Shares
Guess which ASX 300 stock is jumping 8% on a major government contract win
Investing Strategies
The 3 best deals on the ASX today
Investing Strategies
Up 30% this year + 7% dividend yield: Is it too late to buy this super stock?
Broker Notes
2 little-known ASX All Ords shares with 11% and 22% upside potential: broker
Share Gainers
Why Core Lithium, McMillan Shakespeare, Perseus Mining, and Zip shares are climbing today
Investing Strategies
ASX passive income of $200 a week? See how you can do it for $5 per day
Dividend Investing
3 ASX All Ords shares sinking over 5% after trading ex-dividend
Frequently Asked Questions
-
Yes, McMillan Shakespeare historically pays two fully franked dividends a year.
-
McMillan Shakespeare generally pays its shareholder dividends in March and September.
-
McMillan Shakespeare Ltd was listed on the ASX on 15 March 2004.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
12 Sep 2024 | $0.7800 | 100.00% | Final | 27 Sep 2024 |
07 Mar 2024 | $0.7600 | 100.00% | Interim | 22 Mar 2024 |
07 Sep 2023 | $0.6600 | 100.00% | Final | 22 Sep 2023 |
09 Mar 2023 | $0.5800 | 100.00% | Final | 24 Mar 2023 |
26 Oct 2022 | $0.7400 | 100.00% | Final | 10 Nov 2022 |
10 Mar 2022 | $0.3400 | 100.00% | Interim | 25 Mar 2022 |
09 Sep 2021 | $0.3110 | 100.00% | Final | 24 Sep 2021 |
11 Mar 2021 | $0.3020 | 100.00% | Interim | 26 Mar 2021 |
05 Mar 2020 | $0.3400 | 100.00% | Interim | 20 Mar 2020 |
28 Aug 2019 | $0.4000 | 100.00% | Final | 11 Sep 2019 |
07 Mar 2019 | $0.3400 | 100.00% | Interim | 22 Mar 2019 |
13 Sep 2018 | $0.4000 | 100.00% | Final | 28 Sep 2018 |
15 Mar 2018 | $0.3300 | 100.00% | Interim | 29 Mar 2018 |
28 Sep 2017 | $0.0000 | 100.00% | Final | 13 Oct 2017 |
30 Mar 2017 | $0.3100 | 100.00% | Interim | 13 Apr 2017 |
29 Sep 2016 | $0.3400 | 100.00% | Final | 14 Oct 2016 |
31 Mar 2016 | $0.2900 | 100.00% | Interim | 15 Apr 2016 |
16 Sep 2010 | $0.1400 | 100.00% | Final | 15 Oct 2010 |
08 Mar 2006 | $0.0250 | 100.00% | Interim | 29 Mar 2006 |
18 Aug 2005 | $0.0240 | 100.00% | Final | 16 Sep 2005 |
MMS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About McMillan Shakespeare Ltd
McMillan Shakespeare Ltd (ASX: MMS) is an employee benefits provider. Its services include salary packaging, novated leasing, disability plan management and support coordination, asset management, and related financial products and services.
The company's asset management businesses provide motor vehicle leasing and fleet management services, as well as fleet and consumer financing.
McMillan Shakespeare consists of more than 20 subsidiaries, the majority incorporated in Australia but also in New Zealand and the United Kingdom.
MMS Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
20 Nov 2024 | $15.07 | $0.04 | 0.27% | 753,543 | $15.20 | $15.29 | $15.00 |
19 Nov 2024 | $15.03 | $0.16 | 1.08% | 217,014 | $14.86 | $15.11 | $14.80 |
18 Nov 2024 | $14.87 | $0.22 | 1.50% | 186,078 | $14.65 | $14.99 | $14.64 |
15 Nov 2024 | $14.65 | $0.02 | 0.14% | 229,572 | $14.64 | $14.84 | $14.59 |
14 Nov 2024 | $14.63 | $-0.29 | -1.94% | 194,402 | $14.94 | $14.99 | $14.63 |
13 Nov 2024 | $14.92 | $-0.43 | -2.80% | 193,611 | $15.18 | $15.30 | $14.91 |
12 Nov 2024 | $15.35 | $-0.05 | -0.32% | 267,273 | $15.30 | $15.52 | $15.13 |
11 Nov 2024 | $15.40 | $0.20 | 1.32% | 135,714 | $15.38 | $15.51 | $15.27 |
08 Nov 2024 | $15.20 | $0.10 | 0.66% | 225,537 | $15.20 | $15.38 | $15.15 |
07 Nov 2024 | $15.10 | $0.30 | 2.03% | 148,101 | $14.85 | $15.10 | $14.85 |
06 Nov 2024 | $14.80 | $0.13 | 0.89% | 124,798 | $14.71 | $14.91 | $14.64 |
05 Nov 2024 | $14.67 | $0.13 | 0.89% | 188,567 | $14.55 | $14.82 | $14.50 |
04 Nov 2024 | $14.54 | $0.04 | 0.28% | 187,965 | $14.45 | $14.64 | $14.42 |
01 Nov 2024 | $14.50 | $-0.11 | -0.75% | 193,723 | $14.65 | $14.65 | $14.36 |
31 Oct 2024 | $14.61 | $-0.17 | -1.15% | 221,236 | $14.69 | $14.78 | $14.61 |
30 Oct 2024 | $14.78 | $-0.05 | -0.34% | 633,875 | $14.80 | $14.92 | $14.67 |
29 Oct 2024 | $14.83 | $-0.22 | -1.46% | 400,083 | $15.07 | $15.12 | $14.72 |
28 Oct 2024 | $15.05 | $-0.11 | -0.73% | 301,777 | $15.20 | $15.28 | $15.05 |
25 Oct 2024 | $15.16 | $-0.03 | -0.20% | 237,812 | $15.54 | $15.60 | $15.03 |
24 Oct 2024 | $15.19 | $-0.32 | -2.06% | 261,061 | $15.55 | $15.55 | $15.16 |
23 Oct 2024 | $15.51 | $0.24 | 1.57% | 335,523 | $15.30 | $15.53 | $15.22 |
22 Oct 2024 | $15.27 | $-0.24 | -1.55% | 354,863 | $15.50 | $15.60 | $15.22 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
20 Sep 2024 | Arlene Tansey | Buy | 4,500 | $67,320 |
On-market trade.
|
11 Sep 2024 | Arlene Tansey | Buy | 488 | $7,690 |
On-market trade.
|
11 Sep 2024 | Robert (Rob) De Luca | Buy | 8,668 | $137,647 |
Conversion of securities.
|
11 Sep 2024 | Robert (Rob) De Luca | Exercise | 8,668 | $137,647 |
Conversion of securities. 139,323 Performance Rights
|
30 Aug 2024 | Arlene Tansey | Buy | 2,412 | $37,675 |
On-market trade.
|
29 Aug 2024 | Kathryn Parsons | Buy | 1,500 | $23,670 |
On-market trade.
|
27 Aug 2024 | Robert (Rob) De Luca | Expiry | 2,469 | $43,528 |
As advised by the company. Lapsed, 147,991 Rights
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Bruce John Akhurst | Non-Executive Director | Apr 2021 |
Mr Akhurst is currently the Chairman of Tabcorp Holdings Limited and Chair of the Peter McCallum Cancer Foundation. Mr Akhurst was previously the CEO of Sensis, Group MD and General Counsel of Telstra, Partner of Mallesons Stephen Jaques, Council Member of RMIT University and a Director of Vocus Group Limited. Mr Akhurst is considered an independent director under the Company's definition of independence. He is Member of the Risk and Compliance Committee.
|
Mr John G Bennetts | Non-Executive Director | Dec 2003 |
Mr Bennetts is an investor and has been the founder and director of several Australian companies. He owns businesses in varied industries including technology and finance. Mr Bennetts is a Non-Executive Director of Sacred Heart Mission. He was a founder of Cellestis Limited and private equity investment firm, Mooroolbark Investments Pty Limited (M-Group). He has also provided corporate advisory services to a range of companies in Australia and Asia. Prior to the establishment of M-Group, he was a senior executive of pioneering Australian multinational IT company, Datacraft Limited.
|
Mr Ross Chessari | Non-Executive Director | Dec 2003 |
Mr Chessari is a founder and director of the investment manager, SciVentures Investments Pty Limited (SciVentures). Prior to founding SciVentures, Mr Chessari was the Managing Director of ANZ Asset Management and the General Manager of ANZ Trustees. Mr Chessari has participated in the growth and development of the Company.
|
Ms Helen Kurincic | Non-Executive DirectorNon-Executive Chairman | Sep 2018 |
Ms Kurincic has formerly held Board roles across the publicly listed, private, not-for-profit and government sectors including Non-Executive Chair of Integral Diagnostics Limited, Non-Executive Director of Estia Health Limited, insurer HBF Health Limited, Domain Principal Group, DCA Group and Melbourne Health. Past management roles include Chief Operating Officer and Director of Genesis Care from its earliest inception, creating and developing the first and largest radiation oncology and cardiology business across Australia. She is Member of the Risk and Compliance Committee and Member of the People and Culture Committee.
|
Ms Arlene May Tansey | Non-Executive Director | Nov 2022 |
Ms Tansey is a Non-Executive Director of TPG Telecom, Aristocrat Leisure Limited, Lendlease Investment Management, and La Trobe Finance. She is also a Board member of the Australian National Maritime Museum and University of Wollongong Global Enterprises. She is formerly Non-Executive Director of WiseTech Global Limited, Infrastructure NSW and the Australian Institute of Company Directors. Before becoming a non-executive Director, Ms Tansey worked in commercial and investment banking in Australia and in investment banking and law in the United States. She is Member of the Risk and Compliance Committee and Member of the People and Culture Committee.
|
Mr Robert (Rob) De Luca | Chief Executive OfficerManaging Director | May 2022 |
Mr De Luca has over 20 years of experience in the Financial Services, Wealth Management, Disability and Healthcare sectors, including roles as Managing Director of Bankwest, CEO of the National Disability Insurance Agency (NDIA). Prior to joining MMS, Mr De Luca was CEO of Zenitas Healthcare.
|
Ms Kathryn Maree Parsons | Non-Executive Director | May 2020 |
Ms Parsons is currently a Non-Executive Director of Nick Scali Limited and Shape Australia Corporation Limited. She brings to the board finance and risk management experience. Ms Parsons was formerly an audit partner at Ernst & Young where she spent time as a partner in the firm's US, UK and Australian practices. In addition to her audit client responsibilities, she was part of the firm's Oceania Assurance Leadership team as the Professional Practice Director with responsibility for assurance quality and risk management in the region. She is Chair of the Risk and Compliance Committee and Member of the People and Culture Committee.
|
Ms Elizabeth Spooner | Company Secretary | Sep 2024 |
-
|
Elizabeth Spooner | Company Secretary |
-
|
|
A. Conn | Group Chief Financial Officer (CFO) and Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Aust) Ltd | 14,341,226 | 20.59% |
Citicorp Nominees Limited | 9,659,571 | 13.87% |
Jp Morgan Nominees Australia Limited | 9,055,068 | 13.00% |
Chessari Holdings Pty Limited 1 | 6,050,941 | 8.69% |
AP Group Pty Limited | 3,976,229 | 5.71% |
Asia Pac Technology Pty Ltd 2 | 3,068,025 | 4.41% |
UBS Nominees Pty Limited | 1,642,741 | 2.36% |
National Nominees Limited | 1,603,815 | 2.30% |
Ann Leslie Ryan | 1,008,418 | 1.45% |
BNP Paribas Nom Pty Limited | 516,216 | 0.74% |
BNP Paribas Noms Pty Ltd <Agency Lending A/c> | 432,139 | 0.62% |
Bnp Paribas Noms Pty Ltd <Global Markets Drp> | 369,772 | 0.53% |
HSBC Custody Nominees (Australia) Limited <NT Commonwealth Super Corp A/c> | 317,722 | 0.46% |
Neweconomy Com Au Nominees Pty Limited | 316,783 | 0.45% |
MOHL Invest Pty Ltd <MOHL Super Fund A/c> | 310,000 | 0.45% |
Citicorp Nominees Pty Ltd <Colonial First State Inv A/c> | 306,624 | 0.44% |
Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 194,956 | 0.28% |
Mod Enterprises Pty Ltd | 193,139 | 0.28% |
Birdseye No.2 Management Pty Ltd <Birdseye Super No. 2 Fund A/c> | 150,000 | 0.22% |
Netwealth Investments Limited <Wrap Services A/C> | 141,977 | 0.20% |